Comprehensive reproductive healthcare for women with immune-mediated inflammatory diseases: Addressing rheumatoid arthritis, spondyloarthritis and inflammatory bowel disease through life's stages.
Contraception
Fertility
Immune-mediated inflammatory diseases (IMIDs)
Inflammatory bowel disease (IBD)
Menopause
Rheumatoid arthritis (RA)
Sexual health
Spondyloarthritis (SpA)
Journal
Autoimmunity reviews
ISSN: 1873-0183
Titre abrégé: Autoimmun Rev
Pays: Netherlands
ID NLM: 101128967
Informations de publication
Date de publication:
22 Dec 2023
22 Dec 2023
Historique:
received:
30
11
2023
accepted:
19
12
2023
medline:
25
12
2023
pubmed:
25
12
2023
entrez:
24
12
2023
Statut:
aheadofprint
Résumé
Immuno-mediated inflammatory diseases (IMIDs) such as rheumatoid arthritis, spondyloarthritis, and inflammatory bowel disease are characterised by pathophysiological mechanisms wherein the immune system erroneously targets the body's own tissues. This review explores the heightened vulnerability of women with IMIDs, influenced by hormonal modulators like estrogen and progesterone. The challenges this poses are multifaceted, encompassing the impact of active disease and medical treatments throughout life stages, including family planning, fertility, and menopause. From the perspectives of rheumatologists and gastroenterologists, we review current management strategies and underscore the need for a multidisciplinary and life-cycle approach to healthcare for women with IMIDs.
Identifiants
pubmed: 38142899
pii: S1568-9972(23)00241-0
doi: 10.1016/j.autrev.2023.103507
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103507Informations de copyright
Copyright © 2023. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest L.A. and M.P. received an honorarium from Pfizer in connection with the development of this manuscript. G.P. and I.G. are Pfizer employees.